



FROM VISION 2020 TO FUTURE PERSPECTIVES

NANOMEDICINE FOR THERAPY AND DIAGNOSTICS

Thursday, October 3, 2019, 17:00h
Lecture Hall Y16 G05
University of Zurich, Irchel Campus

Andrea Chicca

Co-Founder, CEO and CSO at Synendos Therapeutics AG
Allschwil, Switzerland




New endocannabinoid modulators to treat CNS disorders

Synendos Therapeutics is a spin-off of the University of Bern that develops therapies for unmet needs in neuropsychiatric disorders. Our first-in-class selective endocannabinoid reuptake inhibitors (SERIs) enable restoration of natural functioning of the brain through the modulation of a new drug target in the endocannabinoid system.

SERIs offer a superior safety profile for short and long term use and an improved therapeutic control. Thanks to an innovative self-limiting mechanism of action, SERIs have the potential to become the first effective treatment for unmet needs in neuropsychiatric disorders with benefit for patients, healthcare providers and society.

The presentation is followed by an aperitif and - for a limited number of students - by a dinner with the speaker. For the dinner, contact elisabetta.biglieri@uzh.ch not later than October 1, 2019 by explaining why you would like to meet the speaker.



Organization

The event series From Vision 2020 to Future Perspectives is organized by a committee of PhD students of the PhD Program in Integrative Molecular Medicine (imMed):
Institute of Physiology UZH: Tobias Hasler (chair) | Amalia Ruiz Serrano (chair)
Sophie Dahl | Ilaria Orlando
Institute of Physiology UZH: Elisabetta Biglieri | Merel van Gogh from the PhD Program Cancer Biology
URPP Global Change and Biodiversity: Maria Parreño
Supported by the SUK Program "Doktoratsprogramme".